000905078 001__ 905078
000905078 005__ 20230123101926.0
000905078 0247_ $$2doi$$a10.2967/jnumed.120.250290
000905078 0247_ $$2ISSN$$a0022-3123
000905078 0247_ $$2ISSN$$a0097-9058
000905078 0247_ $$2ISSN$$a0161-5505
000905078 0247_ $$2ISSN$$a1535-5667
000905078 0247_ $$2ISSN$$a2159-662X
000905078 0247_ $$2Handle$$a2128/32294
000905078 0247_ $$2pmid$$a33712532
000905078 0247_ $$2WOS$$aWOS:000770317400004
000905078 037__ $$aFZJ-2022-00377
000905078 082__ $$a610
000905078 1001_ $$0P:(DE-Juel1)166265$$aBischof, Gerard Nisal$$b0$$eCorresponding author
000905078 245__ $$aToward a Universal Readout for 18 F-Labeled Amyloid Tracers: The CAPTAINs Study
000905078 260__ $$aNew York, NY$$bSoc.$$c2021
000905078 3367_ $$2DRIVER$$aarticle
000905078 3367_ $$2DataCite$$aOutput Types/Journal article
000905078 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1667394647_29954
000905078 3367_ $$2BibTeX$$aARTICLE
000905078 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000905078 3367_ $$00$$2EndNote$$aJournal Article
000905078 520__ $$aTo date, 3 18F-labeled PET tracers have been approved for assessing cerebral amyloid plaque pathology in the diagnostic workup of suspected Alzheimer disease (AD). Although scanning protocols are relatively similar across tracers, U.S. Food and Drug Administration- and the European Medicines Agency-approved visual rating protocols differ among the 3 tracers. This proof-of-concept study assessed the comparability of the 3 approved visual rating protocols to classify a scan as amyloid-positive or -negative, when applied by groups of experts and nonexperts to all 3 amyloid tracers. Methods: In an international multicenter approach, both expert (n = 4) and nonexpert raters (n = 3) rated scans acquired with 18F-florbetaben, 18F-florbetapir and 18F-flutemetamol. Scans obtained with each tracer were presented for reading according to all 3 approved visual rating protocols. In a randomized order, every single scan was rated by each reader according to all 3 protocols. Raters were blinded for the amyloid tracer used and asked to rate each scan as positive or negative, giving a confidence judgment after each response. Percentage of visual reader agreement, interrater reliability, and agreement of each visual read with binary quantitative measures (fixed SUV ratio threshold for positive or negative scans) were computed. These metrics were analyzed separately for expert and nonexpert groups. Results: No significant differences in using the different approved visual rating protocols were observed across the different metrics of agreement in the group of experts. Nominal differences suggested that the 18F-florbetaben visual rating protocol achieved the highest interrater reliability and accuracy especially under low confidence conditions. For the group of nonexpert raters, significant differences between the different visual rating protocols were observed with overall moderate-to-fair accuracy and with the highest reliability for the 18F-florbetapir visual rating protocol. Conclusion: We observed high interrater agreement despite applying different visual rating protocols for all 18F-labeled amyloid tracers. This implies that the results of the visual interpretation of amyloid imaging can be well standardized and do not depend on the rating protocol in experts. Consequently, the creation of a universal visual assessment protocol for all amyloid imaging tracers appears feasible, which could benefit especially the less-experienced readers.Keywords: amyloid PET; florbetaben; florbetapir; flutemetamol; visual rating standardization.
000905078 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000905078 536__ $$0G:(DE-HGF)POF4-5254$$a5254 - Neuroscientific Data Analytics and AI (POF4-525)$$cPOF4-525$$fPOF IV$$x1
000905078 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000905078 7001_ $$0P:(DE-HGF)0$$aBartenstein, Peter$$b1
000905078 7001_ $$0P:(DE-HGF)0$$aBarthel, Henryk$$b2
000905078 7001_ $$0P:(DE-HGF)0$$avan Berckel, Bart$$b3
000905078 7001_ $$0P:(DE-HGF)0$$aDoré, Vincent$$b4
000905078 7001_ $$0P:(DE-Juel1)169110$$avan Eimeren, Thilo$$b5
000905078 7001_ $$0P:(DE-HGF)0$$aFoster, Norman$$b6
000905078 7001_ $$0P:(DE-HGF)0$$aHammes, Jochen$$b7
000905078 7001_ $$0P:(DE-HGF)0$$aLammertsma, Adriaan A.$$b8
000905078 7001_ $$0P:(DE-HGF)0$$aMinoshima, Satoshi$$b9
000905078 7001_ $$0P:(DE-HGF)0$$aRowe, Chris$$b10
000905078 7001_ $$0P:(DE-HGF)0$$aSabri, Osama$$b11
000905078 7001_ $$0P:(DE-HGF)0$$aSeibyl, John$$b12
000905078 7001_ $$0P:(DE-HGF)0$$aVan Laere, Koen$$b13
000905078 7001_ $$0P:(DE-HGF)0$$aVandenberghe, Rik$$b14
000905078 7001_ $$0P:(DE-HGF)0$$aVillemagne, Victor$$b15
000905078 7001_ $$0P:(DE-HGF)0$$aYakushev, Igor$$b16
000905078 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b17
000905078 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.120.250290$$gVol. 62, no. 7, p. 999 - 1005$$n7$$p999 - 1005$$tJournal of nuclear medicine$$v62$$x0022-3123$$y2021
000905078 8564_ $$uhttps://juser.fz-juelich.de/record/905078/files/Toward%20a%20Universal%20Readout_fulltext.pdf$$yRestricted$$zStatID:(DE-HGF)0599
000905078 8564_ $$uhttps://juser.fz-juelich.de/record/905078/files/Towards%20a%20Universal%20Readout_Bischof_PostPrint.pdf$$yOpenAccess$$zStatID:(DE-HGF)0510
000905078 909CO $$ooai:juser.fz-juelich.de:905078$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)166265$$a University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany; gerard.bischof@uk-koeln.de.$$b0
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Department of Nuclear Medicine, LMU Munich, Munich, Germany$$b1
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany$$b2
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Amsterdam University Medical Centers, Location VUmc Radiology and Nuclear Medicine, Amsterdam, The Netherlands$$b3
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  CSIRO Health and Biosecurity, Parkville 3052, Victoria, Australia$$b4
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia$$b4
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)169110$$a University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany$$b5
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)169110$$a Department of Neurology, University Hospital Cologne, Cologne, Germany$$b5
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)169110$$a German Center of Neurodegenerative Disease (DZNE), Bonn, Germany$$b5
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah$$b6
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany$$b7
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Amsterdam University Medical Centers, Location VUmc Radiology and Nuclear Medicine, Amsterdam, The Netherlands$$b8
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah$$b9
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  CSIRO Health and Biosecurity, Parkville 3052, Victoria, Australia$$b10
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia$$b10
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany$$b11
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Institute for Neurodegenerative Disorders, New Haven, Connecticut$$b12
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Nuclear Medicine and Molecular Imaging, University Hospital Leuven and Department of Imaging and Pathology KU Leuven, Leuven, Belgium$$b13
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Memory Clinic, University Hospital Leuven and Department of Neurosciences, KU Leuven, Belgium$$b14
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a CSIRO Health and Biosecurity, Parkville 3052, Victoria, Australia$$b15
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia$$b15
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, Technical University of Munich, Germany; and$$b16
000905078 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b17$$kFZJ
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)177611$$a University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany$$b17
000905078 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)177611$$a German Center of Neurodegenerative Disease (DZNE), Bonn, Germany$$b17
000905078 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000905078 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5254$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
000905078 9141_ $$y2022
000905078 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2019$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000905078 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2019$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-27
000905078 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000905078 920__ $$lyes
000905078 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000905078 980__ $$ajournal
000905078 980__ $$aVDB
000905078 980__ $$aUNRESTRICTED
000905078 980__ $$aI:(DE-Juel1)INM-2-20090406
000905078 9801_ $$aFullTexts